Key facts
- Deep Blue BioTech’s last known valuation is $4.2M (Oct 2024).
- It has raised $700K.
- Notable investors include MassChallenge, SFC Capital, Sustainable Ventures, Remove (Netherlands), One Planet Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Deep Blue BioTech
- ·The full record, as it builds
Funding rounds
No funding rounds for Deep Blue BioTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Deep Blue BioTech
Developer of a synthetic biology platform designed to produce carbon-neutral chemicals using photosynthetic cyanobacteria. The company offers a carbon dioxide-based manufacturing process powered by genetically engineered microorganisms, enabling personal care brands to access sustainable and cost-effective ingredients.
- Sector
- Materials and Resources
- HQ
- Stowmarket, United Kingdom
- Founded
- 2023
- Employees
- 5
- Website
- deepbluebiotech.com/
- Ownership
- Privately Held (backing)
Deep Blue BioTech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Deep Blue BioTech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Deep Blue BioTech in its N-PORT filings yet. We sweep new filings monthly.